program. support for important three everyone. Corvus' by start believe to further new Leiv developments and you, I we Today, joining prioritization Thank underscore and CPI-XXX our good call. of for will you advance afternoon, update business highlighting oncology today in Thank that our us opportunity this
data continues peripheral deep lymphoma tumor enrolment is accelerating and T-cell to data; durable the clinical our in be responses. and promising with strong First, in trial
trial. select enable should we identified us likely for In benefit plan CPI-XXX, addition, that a we to biomarker from to as most next which is patients have important our
this randomized request trial. new indicated second to registration and discuss a communication, that they anticipate solid present like responses at clinical brings solid Drug will development, in us We addition preclinical And for months. in In tumors; a pathway place potential the AACR, recent registrational expanding would data cancer. to few tumors, take CPI-XXX. expanding which Administration ITK in we Food immune next us trial III to stimulates new to antitumor third, of a the demonstrating meeting the will Phase meeting that Two, the to XXX to US
target way and an now treatment of diseases. is With to the that introduction, ibrutinib We planned T-cells with to and ITK, that lymphomas and lymphoma CPI-XXX as that for ITK have review several CPI-XXX I key for XXX anti-CDXX a BTK binds we similar specific inhibitors the momentum to covalent with the development elements believe B-cell target the of the months of last BTK. similar T-cell over is binds autoimmune will B-cell inhibitor to built antibodies very the opportunity to and
We are playbook. development, similar Data using other in and diseases. then accelerates expand into immune cancers we a lymphoma and
preclinical system the by additional of trial animal understanding of T-cell Our our clinical strengthened been has function and and by in ITK studies. immune lymphoma laboratory ongoing
broader believe as has in solid tumors, more, and opportunities including stated, we XXX areas learn Simply autoimmunity we allergy. multiple
a have cell shown in playing is differentiation. important helper ITK We that role an target system, immune in the T critical
for cells for cells data Specifically, allergic because the many cells function modulates tumor skewing cells. cancer ThX and required ASH T-cells immune that in at are responsible for important toward Meeting and cells the of especially the by and therapy blocking culprit ThX This ThXX elimination December, cells showing we ThX ThX presented and both diseases. autoimmune ThXX of is and are CPI-XXX
all any Based have we clinical of we aware development, and inhibitors focus a of to efficiently we and our of property ITK on the of resources. XXX have and existing selective with development CPI-XXX not have value build position currently believe other strategy this, inhibitors strong lymphomas in intellectual T-cell covering ITK prioritized a use. are on We methods
dosing, XXX momentum in have biologic the in boxes elucidated that for models, Diving effects our vitro, deeper in number indication for ITK Phase diseases. a We addition immune the preclinical confirmed and X and de-risk and the of broad and into clinical scientific of clinical number important our checked we trial. of across successfully lead CPI-XXX, potential in
blocking lymphoma is cell particularly at patients T-cell last Phase of the important regard induction refractory ASH concept dosing signalling, with we than or one is our T Since the activity This a skewing pioneered. dosing continued receptor as cancer, with XXX ThX have December, lymphoma general requires trial of T-cell In to the in cohort that in enrolment data and peripheral PTCL. update accelerated. in demonstrating milligram has different
tumor XXXX, have response. As enrolled, XX of patients February including valuable XX XX, for been
CR, partial are complete who The for had scan of a highlights patient been was from a and follows. of evaluated nodal continue awaiting tumor duration months has seven patients of XX yet response. therapy, duration. XX one tumor of months complete continued of seven months months partial regression. demonstrate months There pet has been for previous to XX-plus XX duration; updated and including who not There's response a data -- duration on response XX equivocal a complete one as have response one response this confirmation response
tumor plots shown waterfall quarter and fourth issued patients these our results today. release swimmer in are press for The
is later is goal at at Conference updated International cohort Logano, Switzerland. Our year, lymphomas, meeting present malignant in to on the data in this June meeting which this a likely most from medical
an patients cell know mediated functioning that identified We host normal us our supporting we benefit to Further are that antitumor induces have for that T-cells. from most believe XXX a enrich that we now predictive response to should important trials this opportunity, requires biomarker likely allow CPI-XXX.
of We or press for millilitre have XXX data. minimum of X,XXX. above summarizes from observed ALC per blood the absolute release required a ALC Normal that Today's lymphocyte ranges count some is cubic to response. X,XXX
easy of trial. only fits demonstrated mechanism four XXX that disease Briefly, above progression-free X.X is XXX's with have an of on of responses five has far, eight action, meet in now patients survival with eight control incorporated This a about median criterion. biomarker below seen with experience our to tumor in patients the based one phase months. months. of PFS this responses presumed This been is XX% objective eligibility XX.X all and criterion biomarker ALC ALC group with as have our so No for XXX patients ongoing and were and measure,
we ongoing in number Ib regarding trial, trial of this preliminary safety clinical would current in a we my adequate design trial. the patients provide registration the the of recently clinical the the that received believe mentioned from plans development communication and Phase Based introduction, on treated inform clinical enrolment our As of for XXX. efficacy our to FDA rate data
As now discuss recommended we to with plan by FDA, to a them request trial. a clinical meeting registration
standard strategy a is current single agent refractory comparing trial conduct selection. for ALC our to patient XXX using biomarker chemotherapy new in Our PTCL, randomized to
Phase this clinical with the an three improve Standard PFS median a on single which meeting potentially interim significantly to deliver XXX agent will expected previously size similar trial believe approximately required trial II PFS, our months. in can an that FDA. order of with single the We XXX planned has randomized patients trial on This related can demonstrate and a total. arm we definitive timeframe data chemotherapy modest of analysis
consistent is accelerated with rate surrogate as both an FDA clinical up, such the a discusses a can approval response just in with published industry that and That benefit follow endpoint a for full verify or on guidance continued approval controlled single randomized for considerations confirm yesterday. plan by document PFS. endpoint of support This trial support based using like
that tumors. Meeting, modulation been at This present a our weeks XXX at of in presented lymphoma the preclinical effector in a importance T a the on value as resulting and and reinforces increase will for is models of few new differentiation anti-tumor based demonstrating opportunity ITK data solid cells T-cell actionable to responses XX Lugano T-cell eight enhances already Meeting immune ongoing has solid seen update target. key therapeutically will this in in in several Another trial tumors. June. AACR be and In work the we the Moreover, in tumors
we have including asthma, activity fibrosis. demonstrated and models psoriasis, immune In lupus diseases, of preclinical XXX
XXX dermatitis proof for with demonstrated and of which very also disease, is in similar to naturally disease. dogs concept companion occurring We human atopic
list provide to the therapy. the ITK of HIV to inhibition studying and from strategies. reduce the the to validation need tier continue will added opportunities role team critical with ITK to of work immune UCSF the block This for we The chronic lock of modulation. XXX further and February, demonstrating new In in anti-proliferative adds presentation of HIV by potential potential researchers a UCSF, for data potential
lymphoma T-cell and ongoing I laser-focused to III In on the discuss randomized FDA near be term, our with will a meeting registration trial trial. in enrolling Phase Phase we
work. us to atopic approach For novel while to with foundation forward remain an XXX T-cell excited in cancer on and with many atopic the to decided in allow we we have increasingly will focus our R&D cash, of of lymphoma advantages. XXX about for a use the diseases. potential In potential strengthen we dermatitis. space, immune We and conserve pause further have dermatitis, our this intensify This push crowded
In anticipated targeting the addition above, adenosine potential other two antagonist from ipilimumab, and catalysts are CDXX. milestones noted ciforadenant T-cell additional activating our receptor to programs; our lymphoma our there antibody Xa B-cell
line being a for trial cell a trial with Phase run a currently triplet led Anderson by therapy from include MD as Consortium with Vanderbilt, Israel X/Xb in is institutions, the potential cancer ipilimumab and clinical Boston, metastatic by Southwestern. member in Duke and This University nivolumab. first combination which renal of Pennsylvania, Kidney participation of Beth Cancer Michigan, Research other UT University is
patients This on antibody endpoint than to endpoints is in safety, activity antitumor XX our as primary of models our XX% achieve ciforadenant. The demonstrating enrol from was volume. trial anti-CTLA-X studies patients tumor showing in deep ciforadenant reduction PRs who publication in is to responses trial antitumor with and synergy with Phase planned and up of based greater tolerability I of the defined tumor percent The and with of CRs data XXXX, activity. preclinical
improve receiving nivo. with and in shown to plateau and goal groups of PFS is data in only The response responses, patients the XX% Historical prolonged have raise progression-free and This deep approximately are adding XX%. complete those our correlate survival survival on about ciforadenant. reflects by that seen IPI
single for get a feel this efficacy trial. is open in we an will a good anticipate As early label we so trial, -- arm the reminder, that we anticipate
cell clinical I/Ib with Pharmaceuticals relapse mupa For cell together in also started Phase patients patients lung partner refractory head cancer. and alone Angel our with squamous with with in pembrolizumab enrolling in China non-small mupadolimab, cancer trial and neck have a and
the key programs, In III initiatives development. inhibitor to use continued is positioned will in closing, randomized enrolment a look Phase I/Ib from we trial Corvus our including registration ITK quarters. at our The from meeting includes biomarker, providing prioritization in the our anticipate T-cell for data the Phase coming forward believe XXX be Lugano milligram on lymphoma presented milestones the the advanced our new XXX, with updates trial [ph] and in to from uniquely updated we Phase the I these our at interim in program most meeting upcoming key XXX trial partner-driven of mid-year. with of June, discuss a FDA We by data dose,
turn I call operator will the and the questions over answer Operator? for now to period.
